Related Experiment Videos
Epidermal growth factor and corneal wound healing. A multicenter study
1Department of Ophthalmology, Hospital Clínico Universitario, University of Valladolid, Spain.
Cornea
|July 1, 1992
Summary
Topical epidermal growth factor (EGF) eye drops significantly speed healing for traumatic corneal epithelial defects. This safe and effective treatment offers a promising new option for ophthalmologists managing these eye injuries.
Area of Science:
- Ophthalmology
- Regenerative Medicine
- Clinical Trials
Background:
- Traumatic corneal epithelial defects are common eye injuries.
- Current treatments may not always ensure rapid and complete healing.
- Epidermal growth factor (EGF) plays a role in tissue repair.
Purpose of the Study:
- To evaluate the safety, ocular tolerance, and efficacy of an ophthalmic solution containing epidermal growth factor (EGF).
- To assess EGF's effectiveness in treating patients with traumatic corneal epithelial defects.
Main Methods:
- A randomized, double-blind, placebo-controlled, multicenter clinical trial.
- 104 patients with traumatic corneal epithelial defects were enrolled.
- Patients received either an ophthalmic solution of EGF or a placebo (vehicle).
Main Results:
- EGF treatment significantly reduced mean epithelial healing time (44.17 hours) compared to placebo (61.05 hours) (p < 0.01).
- A significantly greater number of EGF-treated patients showed complete epithelial healing at 24, 48, and 72 hours.
- The ophthalmic solution of EGF demonstrated adequate local tolerance in all patients.
Conclusions:
- Topical EGF is a well-tolerated and effective treatment for traumatic corneal epithelial defects.
- EGF ophthalmic solutions represent a significant advancement for ophthalmologists in managing corneal injuries.
- Further research may explore EGF's potential in other ocular surface conditions.